{"id":36195,"date":"2023-08-23T17:22:54","date_gmt":"2023-08-23T15:22:54","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-annonce-la-publication-dans-advances-in-therapy-de-la-premiere-comparaison-indirecte-ajustee-par-appariement-entre-cabometyx-cabozantinib-et-le-regorafenib-dans-le-traitement-du-carcinom\/"},"modified":"2024-08-09T07:30:27","modified_gmt":"2024-08-09T05:30:27","slug":"ipsen-annonce-la-publication-dans-advances-in-therapy-de-la-premiere-comparaison-indirecte-ajustee-par-appariement-entre-cabometyx-cabozantinib-et-le-regorafenib-dans-le-traitement-du-carcinom-2","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-publication-dans-advances-in-therapy-de-la-premiere-comparaison-indirecte-ajustee-par-appariement-entre-cabometyx-cabozantinib-et-le-regorafenib-dans-le-traitement-du-carcinom-2\/","title":{"rendered":"Ipsen annonce la publication dans Advances in Therapy de la premi\u00e8re comparaison indirecte ajust\u00e9e par appariement entre Cabometyx\u00ae (cabozantinib) et le r\u00e9goraf\u00e9nib dans le traitement du carcinome h\u00e9patocellulaire avanc\u00e9"},"content":{"rendered":"